dihexa fda approval status 2026 clinical trial dihexa human trials SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders DHX / PNB-0408 - Pure

GHK-Cu does not inhibit ghrelin, does not stimulate GLP-1 receptors, and does not meaningfully alter insulin sensitivity

Visit our store or call us

As of 2026, retatrutide has not received marketing authorisation from the MHRA or EMA and is only accessible within authorised clinical trials

Research suggests that it works by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat accumulation), particularly in stubborn fat deposits such as the abdomen and thighs

The following information reflects dosages commonly reported in research literature and anecdotal use

We Have Everything You Need To Get Started